MYD88 expression and L265P mutation in diffuse large B-cell lymphoma

Human Pathology

Volumn 44, Issue 7, 2013, Pages 1375-1381

  Choi, Jung Woo ^a   Kim, Younghye ^a   Lee, Ju Han ^a   Kim, Young Sik ^a  

^a Korea University   (South Korea)

Author keywords

Mutation; MYD88; Non Hodgkin lymphoma

Indexed keywords

L265P PROTEIN; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA SEQUENCE; FEMALE; GENE EXPRESSION PROFILING; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPHOMA CELL; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION;

DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MYELOID DIFFERENTIATION FACTOR 88; NEOPLASM RECURRENCE, LOCAL; POINT MUTATION; POLYMERASE CHAIN REACTION; REPUBLIC OF KOREA; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84879210992     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2012.10.026     Document Type: Article

References (24)

1. B. Coiffier, C. Thieblemont, and E. Van Den Neste Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte Blood 116 2010 2040 2045
2. A.A. Alizadeh, M.B. Eisen, and R.E. Davis Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling Nature 403 2000 503 511
3. M. Compagno, W.K. Lim, and A. Grunn Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma Nature 459 2009 717 721
4. R.E. Davis, V.N. Ngo, and G. Lenz Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma Nature 463 2010 88 92
5. V.N. Ngo, R.M. Young, and R. Schmitz Oncogenically active MYD88 mutations in human lymphoma Nature 470 2011 115 119
6. K.A. Lord, B. Hoffman-Liebermann, and D.A. Liebermann Complexity of the immediate early response of myeloid cells to terminal differentiation and growth arrest includes ICAM-1, Jun-B and histone variants Oncogene 5 1990 387 396
7. T. Kawai, and S. Akira The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors Nat Immunol 11 2010 373 384
8. I. Coste, K. Le Corf, and A. Kfoury Dual function of MyD88 in RAS signaling and inflammation, leading to mouse and human cell transformation J Clin Invest 120 2010 3663 3667
9. S. Rakoff-Nahoum, and R. Medzhitov Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88 Science 317 2007 124 127
10. M. Montesinos-Rongen, E. Godlewska, A. Brunn, O.D. Wiestler, R. Siebert, and M. Deckert Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma Acta Neuropathol 122 2011 791 792
11. A. Pham-Ledard, D. Cappellen, F. Martinez, B. Vergier, M. Beylot-Barry, and J.P. Merlio MYD88 somatic mutation is a genetic feature of primary cutaneous diffuse large B-cell lymphoma, leg type J Invest Dermatol 132 2012 2118 2120
12. J.G. Lohr, P. Stojanov, and M.S. Lawrence Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing Proc Natl Acad Sci U S A 109 2012 3879 3884
13. R.D. Morin, M. Mendez-Lago, and A.J. Mungall Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma Nature 476 2011 298 303
14. L. Pasqualucci, V. Trifonov, and G. Fabbri Analysis of the coding genome of diffuse large B-cell lymphoma Nat Genet 43 2011 830 837
15. H. Stein, R.A. Warnke, and W.C. Chan Diffuse large B-cell lymphoma, not otherwise specified S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele, J.W. Vardiman, WHO classification of tumours of haematopoietic and lymphoid tissues 2008 IARC Press Lyon 233 237
16. C.P. Hans, D.D. Weisenburger, and T.C. Greiner Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray Blood 103 2004 275 282
17. E.L. Wang, Z.R. Qian, and M. Nakasono High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer Br J Cancer 102 2010 908 915
18. Y. Zhu, J.M. Huang, G.N. Zhang, X. Zha, and B.F. Deng Prognostic significance of MyD88 expression by human epithelial ovarian carcinoma cells J Transl Med 10 2012 77
19. S. Akira, and K. Takeda Toll-like receptor signalling Nat Rev Immunol 4 2004 499 511
20. K.H. Lim, Y. Yang, and L.M. Staudt Pathogenetic importance and therapeutic implications of NF-kappaB in lymphoid malignancies Immunol Rev 246 2012 359 378
21. J.B. Swann, M.D. Vesely, and A. Silva Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis Proc Natl Acad Sci U S A 105 2008 652 656
22. G.J. Ruiz-Delgado, D. Gomez-Almaguer, and L.C. Tarin-Arzaga Is there a benefit to adding rituximab to CHOP in the overall survival of patients with B-cell non-Hodgkin's lymphoma in a developing country? Hematology 17 2012 193 197
23. J.N. Winter, E.A. Weller, and S.J. Horning Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study Blood 107 2006 4207 4213
24. K. Fu, D.D. Weisenburger, and W.W. Choi Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma J Clin Oncol 26 2008 4587 4594